Promising Biotech Stocks To Consider – November 13th

Moderna, AbbVie, Alnylam Pharmaceuticals, Danaher, and Natera are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science to develop products or services, such as medicines, vaccines, and diagnostic tests. For investors, they can offer growth potential but often carry substantial risk because a company’s value may depend on clinical-trial results, regulatory approvals, and funding needs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of MRNA traded down $4.85 on Friday, reaching $226.50. The stock had a trading volume of 3,217,132 shares, compared to its average volume of 12,550,142. Moderna has a twelve month low of $22.28 and a twelve month high of $280.80. The firm has a market capitalization of $91.65 billion, a PE ratio of -31.90 and a beta of 1.16. The firm has a 50-day moving average of $200.18 and a 200 day moving average of $95.52. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV stock traded down $0.26 during midday trading on Friday, hitting $294.19. 1,079,083 shares of the stock were exchanged, compared to its average volume of 6,287,794. The stock’s 50-day moving average price is $274.82 and its 200-day moving average price is $240.55. The stock has a market cap of $520.01 billion, a price-to-earnings ratio of 50.61, a PEG ratio of 1.34 and a beta of 0.20. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $302.93.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Shares of NASDAQ ALNY traded up $8.60 during trading on Friday, reaching $165.25. The company had a trading volume of 1,355,467 shares, compared to its average volume of 1,597,090. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18. Alnylam Pharmaceuticals has a twelve month low of $149.18 and a twelve month high of $479.79. The stock has a 50-day moving average price of $221.24 and a two-hundred day moving average price of $276.94. The stock has a market capitalization of $22.13 billion, a PE ratio of 8.53 and a beta of 0.42.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of DHR traded down $2.04 during trading hours on Friday, reaching $230.12. 776,930 shares of the company traded hands, compared to its average volume of 4,415,372. The stock has a market capitalization of $161.90 billion, a PE ratio of 37.68, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. The stock has a fifty day simple moving average of $222.11 and a 200 day simple moving average of $201.53. Danaher has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45.

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

NTRA stock traded down $8.38 during trading on Friday, hitting $314.56. The stock had a trading volume of 549,112 shares, compared to its average volume of 1,462,445. The company’s 50 day moving average price is $379.87 and its two-hundred day moving average price is $271.22. Natera has a 1-year low of $181.00 and a 1-year high of $437.41. The stock has a market cap of $45.61 billion, a price-to-earnings ratio of -276.28 and a beta of 1.55.